News

The Alzheimer’s community lamented Eli Lilly’s recent announcement that its experimental therapy solanezumab failed to demonstrate efficacy in treating the disease in recent clinical trials. In the announcement, released Nov. 23, Lilly said it would not pursue regulartory approval for the drug. Solanezumab’s inability to demonstrate effectiveness in people with mild demential due to…

The Alzheimer’s Association has awarded a $118,673 grant to a researcher at Boston University School of Medicine to study how obesity affects brain aging and, potentially, a person’s risk of Alzheimer’s disease or dementia. The researcher, Claudia Satizabal, has been associated for several years with the Framingham Heart Study, working with Dr.

Anavex Life Sciences reported that its experimental drug Anavex 2-73 prevented further decline in mental capacity in a small Phase 2a trial involving 32 patients with mild to moderate Alzheimer’s disease. Although the trial was not designed to prove the treatment’s effectiveness, after about 10 months, patients had the same mental acuity…

A process believed to trigger toxicity and neuron death in Alzheimer’s disease may actually work to protect neurons in early disease stages — a finding that may be translated into treatments that boost this protective effect. Phosphorylated tau, which tends to aggregate into tangles inside neurons and is widely believed to…

Cognition Therapeutics has announced the dosing of the first Alzheimer’s patient in a Phase 1b clinical trial of its drug candidate, CT1812, for the treatment of mild to moderate Alzheimer’s disease (AD). CT1812 is a proprietary, first-in-class, orally available, drug-like small molecule designed to displace bound amyloid beta oligomers (molecules thought to be…

Brain training can improve both memory and mood in people with mild cognitive impairment, but once a dementia diagnosis has been made, the training no longer has an impact. In the study, “Computerized Cognitive Training in Older Adults With Mild Cognitive Impairment or Dementia: A Systematic Review…

Researchers from Iran show in the first human trial that probiotics appear to improve brain cognition in humans. The study, “Effect of Probiotic Supplementation on Cognitive Function and Metabolic Status in Alzheimer’s Disease: A Randomized, Double-Blind and Controlled Trial,” was published in the open-access journal Frontiers in Aging Neuroscience.

A new research study has found that older, cognitively normal adults with elevated levels of cortical amyloid, the protein linked to Alzheimer’s, are much more likely to report feeling lonely and socially isolated regardless of their circumstances. These findings support the potential role of loneliness in preclinical Alzheimer’s disease.

AdAlta and Crossbeta Biosciences have entered into a commercialization agreement, granting Crossbeta with a license to three beta-amyloid oligomer (AßO)-specific shark antibodies, considered to have disease-specific potential for the diagnosis and treatment of Alzheimer’s disease (AD). These three shark antibodies were identified under a December 2013 agreement between…

Merck’s amyloid-lowering drug, verubecestat, has proceeded to Phase 3 clinical trials after early studies showed it safely lowered the levels of amyloid-beta, the protein linked to neurodegeneration in the brains of Alzheimer’s disease patients. Although the news may be reason for optimism, it remains to be seen if the treatment…